Scope
Reference
DAC20289
Description
Procurement of PRRT (Peptide Receptor Radionuclide Therapy)
Contract 1. PRRT (Peptide Receptor Radionuclide Therapy)
Supplier
Contract value
- £1,820,000 excluding VAT
- £2,184,000 including VAT
Above the relevant threshold
Date signed
24 November 2025
Contract dates
- 24 November 2025 to 31 December 2026
- 1 year, 1 month, 7 days
Main procurement category
Goods
CPV classifications
- 33000000 - Medical equipments, pharmaceuticals and personal care products
Contract locations
- UKN - Northern Ireland
Justification for not setting key performance indicators
Not required as total of contract is below the £5M threshold
Other information
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Single supplier - intellectual property or exclusive rights
Under Schedule 5 of the PA2023, only one supplier can supply these goods as they have exclusive rights and hold the unique patent and licence for this product. Lutathera is a licenced radiopharmaceutical for specialised patient treatments.
Supplier
NOVARTIS PHARMACEUTICALS UK LIMITED
- Companies House: 00119006
- Public Procurement Organisation Number: PJTX-5182-QVLR
2nd Floor, The Westworks Building White City Place
London
W12 7FQ
United Kingdom
Email: commercial.pricing@novartis.com
Website: https://www.novartis.com/uk-en/
Region: UKI33 - Kensington & Chelsea and Hammersmith & Fulham
Small or medium-sized enterprise (SME): No
Voluntary, community or social enterprise (VCSE): No
Supported employment provider: No
Public service mutual: No
Contract 1
Contracting authority
Belfast Health & Social Care Trust
- Public Procurement Organisation Number: PLQJ-5727-JCLR
Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom
Region: UKN06 - Belfast
Organisation type: Public authority - central government
Devolved regulations that apply: Northern Ireland